Search

Your search keyword '"Carlota Jimeno"' showing total 9 results
Start Over Author "Carlota Jimeno"
9 results on '"Carlota Jimeno"'

1. THU-114 Alkaline phosphatase levels at 6 months as a predictor of response to ursodeoxycholic acid at 1 year in patients with primary biliary cholangitis

Author

Sendra, Carmen, primary, del Pilar Silva-Ruiz, María, additional, Mate, Carlota Jimeno, additional, Ruiz, Patricia Cordero, additional, Pérez-Palacios, Domingo, additional, Romero, Gema, additional, Angulo-Mcgrath, Isabela, additional, Quiros-Rivero, Pablo, additional, Rosales-Zábal, Jose Miguel, additional, and Sousa-Martin, Jose Manuel, additional

Published
2024
Full Text
View/download PDF

2. Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

Author

Ruíz-Cobo, Juan Carlos, primary, Llaneras, Jordi, additional, Buti, Maria, additional, Forns, Xavier, additional, Conde, Isabel, additional, Almeida, Ana Arencibia, additional, Diago, Moises, additional, Garcia-Samaniego Rey, Francisco Javier, additional, Alonso, José Castellote, additional, Llerena, Susana, additional, Rodriguez, Elisa, additional, Muñoz, Beatriz Mateos, additional, Rodríguez, Manuel, additional, Vázquez, Inmaculada Fernández, additional, Rosales Zabal, Jose Miguel, additional, Calleja Panero, José Luis, additional, Morillas, Rosa M, additional, Montoliu, Silvia, additional, Moya, Adolfo Gallego, additional, Andrade, Raul J., additional, Guerra, Manuel Hernández, additional, Badia-Aranda, Esther, additional, Mate, Carlota Jimeno, additional, Santiago, Jesús González, additional, Cuenca, Beatriz, additional, Monterde, Vanesa Bernal, additional, Delgado, Manuel, additional, Turnes, Juan, additional, and Lens, Sabela, additional

Published
2023
Full Text
View/download PDF

3. The combination of LACE index, MELD on discharge and a previous history of decompensation defines risk groups for early readmission in patients with liver cirrhosis

Author

Sánchez, Yolanda, primary, Rosales Zabal, Jose Miguel, additional, Carmona, Isabel, additional, Casado, Marta, additional, Mate, Carlota Jimeno, additional, Torres, Ana, additional, Alvarez, Paula Fernandez, additional, Cortes, Miren Garcia, additional, Garcia, Alberto Garcia, additional, Alañón, Paloma, additional, Lopez Garrido, Maria Angeles, additional, Gomez, Manuel Romero, additional, Sendra, Carmen, additional, Estevez, Matias, additional, Jiménez, Miguel, additional, and Ampuero, Javier, additional

Published
2023
Full Text
View/download PDF

4. Current status of hepatitis delta in Andalusia: multicenter study

Author

Casado, Marta, primary, Castillo, Anny Camelo, additional, Baena, Pilar Barrera, additional, Perez Jimenez, Ana Belen, additional, Bandera, Jose Pinazo, additional, Viciana, Isabel, additional, Aguilar, Juan Cristobal, additional, Carlos, Juan, additional, Arboledas, Alados, additional, SantaMaria Rodriguez, German Jose, additional, Freyre, Carolina, additional, Villalba, Carmen Molina, additional, Coronas, Joaquin Salas, additional, Luzón-García, M. Pilar, additional, Ruiz, Elena, additional, Fernandez, Teresa Cabezas, additional, del Pino, Pilar, additional, De La Luna, Francisco Franco Álvarez, additional, Cordero, Patricia, additional, Arellano, Encarnación Ramirez, additional, Giráldez-Gallego, Alvaro, additional, Lozano Domínguez, María Carmen, additional, Lopez Garrido, Maria Angeles, additional, Sampedro, Antonio, additional, González-Grande, Rocio, additional, Palop, Begoña, additional, Macías, Manuel, additional, Montiel, Natalia, additional, Molina, Laura Castillo, additional, Roldan, Carolina, additional, Fernández, Carmen Sendra, additional, De La Iglesia Salgado, Alberto, additional, Mate, Carlota Jimeno, additional, del Carmen Domínguez, Maria, additional, Fernández-Sánchez, Fernando, additional, Rosales Zabal, Jose Miguel, additional, and Garcia, Federico Garcia, additional

Published
2023
Full Text
View/download PDF

5. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C

Author

Martin Bonacci, Aida Ortega-Alonso, Jose Luis Calleja, Manuel de la Mata, Raúl J. Andrade, Maria Buti, Guillermo Ontanilla, Juan José Urquijo, Javier Crespo, Juan Manuel Pascasio, Carlota Jimeno, José María Moreno-Planas, José Miguel Rosales, Nieves Palomo, Xavier Forns, Isabel Carmona, Marta Hernández, Blanca Figueruela, Francisco Javier Serrano, Manuel Romero-Gómez, M. Maraver, Javier Salmerón, Ángela Rojas, Javier Ampuero, R. Quiles, Susana Llerena, P. Cordero, J.M. Navarro, and Moisés Diago

Subjects
Male, medicine.medical_specialty, Cirrhosis, Survival, Sustained Virologic Response, Bilirubin, Charlson index, Comorbidity, Antiviral Agents, Models, Biological, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, Liver disease, 0302 clinical medicine, Internal medicine, Outcome Assessment, Health Care, medicine, Humans, Prospective Studies, Stage (cooking), Aged, Proportional Hazards Models, Hepatology, business.industry, Hazard ratio, Viral eradication, Hepatitis C, Middle Aged, Prognosis, medicine.disease, chemistry, Spain, 030220 oncology & carcinogenesis, Multivariate Analysis, Female, 030211 gastroenterology & hepatology, Liver function, business, Algorithms
Abstract

Background & Aims: Patients with advanced liver fibrosis remain at risk of cirrhosis-related outcomes and those with severe comorbidities may not benefit from hepatitis C (HCV) eradication. We aimed to collect data on all-cause mortality and relevant clinical events within the first two years of directacting antiviral therapy, whilst determining the prognostic capability of a comorbidity-based model. Methods: This was a prospective non-interventional study, from the beginning of direct-acting antiviral therapy to the event of interest (mortality) or up to two years of follow-up, including 14 Spanish University Hospitals. Patients with HCV infection, irrespective of liver fibrosis stage, who received direct-acting antiviral therapy were used to build an estimation and a validation cohort. Comorbidity was assessed according to Charlson comorbidity and CirCom indexes. Results: A total of 3.4% (65/1,891) of individuals died within the first year, while 5.4% (102/1,891) died during the study. After adjusting for cirrhosis, platelet count, alanine aminotransferase and sex, the following factors were independently associated with one-year mortality: Charlson index (hazard ratio [HR] 1.55; 95% CI 1.29-1.86; p = 0.0001), bilirubin (HR 1.39; 95% CI 1.11-1.75; p = 0.004), age (HR 1.06 95% CI 1.02-1.11; p = 0.005), international normalized ratio (HR 3.49; 95% CI 1.36-8.97; p = 0.010), and albumin (HR 0.18; 95% CI 0.09-0.37; p = 0.0001). HepCom score showed a good calibration and discrimination (C-statistics 0.90), and was superior to the other prognostic scores (model for end-stage liver disease 0.81, ChildPugh 0.72, CirCom 0.68) regarding one-and two-year mortality. HepCom score identified low- (= 25 points: 56%-59%) mortality groups, both in the estimation and validation cohorts. The distribution of clinical events was similar between groups. Conclusions: The HepCom score, a combination of Charlson comorbidity index, age, and liver function (international normalized ratio, albumin, and bilirubin) enables detection of a group at high risk of one-and two-year mortality, and relevant clinical events, after starting direct-acting antiviral therapy. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Published
2018
Full Text
View/download PDF

6. THU-216 - Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

Author

Ruíz-Cobo, Juan Carlos, Llaneras, Jordi, Buti, Maria, Forns, Xavier, Conde, Isabel, Almeida, Ana Arencibia, Diago, Moises, Garcia-Samaniego Rey, Francisco Javier, Alonso, José Castellote, Llerena, Susana, Rodriguez, Elisa, Muñoz, Beatriz Mateos, Rodríguez, Manuel, Vázquez, Inmaculada Fernández, Rosales Zabal, Jose Miguel, Calleja Panero, José Luis, Morillas, Rosa M, Montoliu, Silvia, Moya, Adolfo Gallego, Andrade, Raul J., Guerra, Manuel Hernández, Badia-Aranda, Esther, Mate, Carlota Jimeno, Santiago, Jesús González, Cuenca, Beatriz, Monterde, Vanesa Bernal, Delgado, Manuel, Turnes, Juan, and Lens, Sabela

Published
2023
Full Text
View/download PDF

7. WED-208 - Current status of hepatitis delta in Andalusia: multicenter study

Author

Casado, Marta, Castillo, Anny Camelo, Baena, Pilar Barrera, Perez Jimenez, Ana Belen, Bandera, Jose Pinazo, Viciana, Isabel, Aguilar, Juan Cristobal, Carlos, Juan, Arboledas, Alados, SantaMaria Rodriguez, German Jose, Freyre, Carolina, Villalba, Carmen Molina, Coronas, Joaquin Salas, Luzón-García, M. Pilar, Ruiz, Elena, Fernandez, Teresa Cabezas, del Pino, Pilar, De La Luna, Francisco Franco Álvarez, Cordero, Patricia, Arellano, Encarnación Ramirez, Giráldez-Gallego, Alvaro, Lozano Domínguez, María Carmen, Lopez Garrido, Maria Angeles, Sampedro, Antonio, González-Grande, Rocio, Palop, Begoña, Macías, Manuel, Montiel, Natalia, Molina, Laura Castillo, Roldan, Carolina, Fernández, Carmen Sendra, De La Iglesia Salgado, Alberto, Mate, Carlota Jimeno, del Carmen Domínguez, Maria, Fernández-Sánchez, Fernando, Rosales Zabal, Jose Miguel, and Garcia, Federico Garcia

Published
2023
Full Text
View/download PDF

8. WED-341 - The combination of LACE index, MELD on discharge and a previous history of decompensation defines risk groups for early readmission in patients with liver cirrhosis

Author

Sánchez, Yolanda, Rosales Zabal, Jose Miguel, Carmona, Isabel, Casado, Marta, Mate, Carlota Jimeno, Torres, Ana, Alvarez, Paula Fernandez, Cortes, Miren Garcia, Garcia, Alberto Garcia, Alañón, Paloma, Lopez Garrido, Maria Angeles, Gomez, Manuel Romero, Sendra, Carmen, Estevez, Matias, Jiménez, Miguel, and Ampuero, Javier

Published
2023
Full Text
View/download PDF

9. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.

Author

Ruiz-Cobo JC, Llaneras J, Forns X, Gallego Moya A, Conde Amiel I, Arencibia A, Diago M, García-Samaniego J, Castellote J, Llerena S, Rodríguez-Seguel E, Mateos B, Rodríguez M, Rosales Zabal JM, Fernández I, Calleja JL, Morillas RM, Montoliu S, Andrade RJ, Badia Aranda E, Hernández-Guerra M, Maté CJ, González-Santiago JM, de Cuenca B, Bernal-Monterde V, Delgado M, Turnes J, Lens S, and Buti M

Subjects
Humans, Male, Female, Middle Aged, Retrospective Studies, Aged, Pyrrolidines therapeutic use, Lactams, Macrocyclic therapeutic use, Drug Combinations, Leucine analogs & derivatives, Leucine therapeutic use, Drug Therapy, Combination, Treatment Outcome, Hepacivirus genetics, Hepacivirus drug effects, Benzopyrans, Hepatitis C, Chronic drug therapy, Heterocyclic Compounds, 4 or More Rings therapeutic use, Antiviral Agents therapeutic use, Sofosbuvir therapeutic use, Carbamates therapeutic use, Sulfonamides therapeutic use, Benzimidazoles therapeutic use, Quinoxalines therapeutic use, Aminoisobutyric Acids, Proline analogs & derivatives, Proline therapeutic use, Cyclopropanes therapeutic use, Sustained Virologic Response
Abstract

Background: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB)., Methods: Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022., Results: In total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non-GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR., Conclusion: SOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first-line therapy with SOF/VEL were not associated with lower SVRs., (© 2024 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results